Please select the eligibility criteria that correspond to the clinical trial below.
Title: Evaluation of Self-monitoring of Oral antiCoagulant therApy by the PatiEnts
Brief Summary: The purpose of this study is to determine whether self-management of oral anticoagulation therapy with warfarin has an effect on patient's quality of life following a specific training program led by pharmacists.


Options:
A: Inclusion Criteria:

* Blood pressure inadequate control (systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 100 mmHg) or
* Diabetes mellitus inadequate Control( ≥ 200 mg/dL) or hypoglycemia moderate or severe
* Be referred to clinical care.

Exclusion Criteria:

* \< 18 years
* Not resident of Porto Alegre
* Diabetes mellitus type I
* Unable to answer the questionnaire or to sign the informed consent form
* Hospital admission
* Death
B: Inclusion Criteria:

* Patient aged 18 years and over followed at the Montreal Heart Institute's Anticoagulation clinic
* Warfarin treatment planned for at least 4 months after inclusion in the study
* Warfarin treatment initiated for at least 6 months
* Last 2 INRs between 1.5 and 4 if target INR is between 2 and 3
* Last 2 INRS between 2 and 4 if target INR is between 2.5 and 3.5
* Provide a signed informed consent

Exclusion Criteria:

* Patient unable to understand (spoken and written) French or English
* Patient refuses or is unable to attend the required training sessions
* Targeted INR other than 2 to 3 or 2.5 to 3.5
* Handicap or physical limitation compromising the patient's ability to initiate self-monitoring in the absence of a proxy helper
* Moderate to severe cognitive impairment or important comprehension problems
* Active neoplasm
* Concurrent chemotherapy
* Hypercoagulable conditions
* Life expectancy of less than 1 year documented in the medical chart
* Inclusion (at time of inclusion or 30 days prior to inclusion) in another research project involving a drug
* Patient anticoagulated with nicoumalone
* Pregnancy or breastfeeding
* Active bleeding (except for menses)
* Recent major bleeding (less than 3 months before inclusion)
* Stroke, acute coronary syndrome, percutaneous coronary intervention, coronary artery bypass graft, cardiac valve replacement, deep veinous thrombosis or pulmonary embolism in the 3 months prior to inclusion
* Any other condition that, in the opinion of the investigators, of the treating physician or of the healthcare professionals working at the anticoagulation clinic could make self-management by the patient impossible
C: Inclusion Criteria:

* receipt of primary care at a VISN 10 Northeast Ohio CBOC
* GFR (calculated according to the 4 variable Modification of Diet in Renal Disease study equation) less than 45 mL/min per 1.73m2 with a second GFR less than 60 at least 90 to 730 days prior to the index GFR (26); and
* at least one primary care visit in the year prior to study initiation.

Exclusion Criteria:

* ESRD as defined by chronic renal replacement therapy,
* receipt of a renal transplant,
* hospice care, and
* age greater than 85 years or less than 18 years at the time of study initiation.
D: Inclusion Criteria:

* Patients prescribed medication(s) for at least one of the following conditions: type 2 diabetes, hyperlipidemia

Exclusion Criteria:

* Patients living outside of England
* Patients with no access to a telephone
* Patients under the age of 18
* Patients unable to give written informed consent
* Patients on drugs for dementia
* Patients showing signs of dementia or cognitive impairment in conversation
* Patients with substantial hearing or sight impairment
* Patients whose medications are ordered by a caregiver/family member
* Patients with insufficient English to take part in the telephone intervention
* Patients living with someone already taking part in the study
* Patients newly prescribed a medication for the conditions listed in the inclusion criteria

Answer: B